Paragon Bioservices has named Gerard Fleury as its chief financial officer (CFO).
Filling in a major leadership role in Paragon Bioservices, Fleury brings with him expertise in strategic and financial health honed during his more than 25 years of working with on leadership teams for companies in the biotech, pharmaceutical, healthcare IT and software industries.
"Our rapid growth, driven by the expanding needs of our client-base over the last few years, has warranted our need to invest in the ranks and capabilities of Paragon's leadership team," Pete Buzy, president and CEO of Paragon Bioservices, said. "Our focus has been on assembling experts at every level of the organization to expand our capabilities to Phase 3/Commercial to address our clients' continually advancing needs. As our new CFO, Gerard is an important addition to our leadership team who joins Paragon on the heels of several promotions and new executive hires we announced earlier this year."
Fleury graduated from Towson University in Maryland with a bachelor's degree in business administration.
"Paragon is one of the preeminent leaders in the CDMO space for gene therapies and biologics, and it has experienced dramatic growth and success in recent years," Fleury said recently. "I am thrilled to join Pete and the rest of the leadership team to assist them in building a world-class company capable of delivering on client needs throughout the life cycles of their products."